目的 分析恩替卡韋與阿德福韋酯對(duì)慢性乙型肝炎的成本-效果。方法 將84例慢性乙型肝炎患者隨機(jī)分為恩替卡韋組40例和阿德福韋酯組44例治療，兩組均治療觀察12個(gè)月。運(yùn)用藥物經(jīng)濟(jì)學(xué)方法分析其成本-效果（C/E）。結(jié)果 治療3個(gè)月恩替卡韋組丙氨酸氨基轉(zhuǎn)移酶（ALT）復(fù)常率明顯高于阿德福韋酯組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；治療6、12個(gè)月兩組ALT復(fù)常率無明顯差異。治療3、6、12個(gè)月恩替卡韋組乙型肝炎病毒（HBV）-DNA轉(zhuǎn)陰率均明顯高于阿德福韋酯組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療3、6、12個(gè)月恩替卡韋組乙型肝炎E抗原（HBeAg）轉(zhuǎn)陰率均明顯高于阿德福韋酯組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療12個(gè)月恩替卡韋組的ALT復(fù)常率、HBV-DNA轉(zhuǎn)陰率、HBeAg轉(zhuǎn)陰率的C/E分別為273.3、352.6、911.0，阿德福韋酯組分別為194.2、328.6、908.6。將阿德福韋酯組作為參照，恩替卡韋組HBV-DNA轉(zhuǎn)陰率及HBeAg轉(zhuǎn)陰率的增量成本-效果（△C/△E）分別為129.7、182.1。結(jié)論 從短期看，阿德福韋酯治療慢性乙型肝炎的療效尚可，藥物經(jīng)濟(jì)學(xué)價(jià)值較高，而恩替卡韋雖然療效更好，但療效與成本尚未達(dá)到理想的平衡。

Objective To analysis the cost-effectiveness analysis of different drugs in patients with chronic hepatitis B.Methods 84 patients with chronic hepatitis B were randomly divided into Entecavir (ETV) group with 40 cases and Adefovir dipivoxil (ADV) group with 44 cases, and pharmacoeconomic analysis of cost effectiveness (C/E) were conducted.Results ALT complex rate, HBVDNA negative rate and HBeAg negative rate after 12 months treatment of the ETV group were 100.0%, 77.5% and 30.0%, and of the ADV group were 100.0%, 59.1% and 13.6%, the HBV-DNA negative rate and HBeAg negative rate between the two groups were statistical significant (P<0.05). The C/E of ALT complex rate, HBV-DNA negative rate and HBeAg negative rate of the ETV group were 273.3,352.6 and 911.0, and of the ADV group were 194.2,328.6 and 908.6.ADV group as a reference, the △C/△E of HBV-DNA negative rate and HBeAg negative rate of the ETV group were 129.7 and 182.1.Conclusions In the short term, Adefovir dipivoxil in the treatment of chronic hepatitis B is acceptable, the value of pharmacoeconomics is high, but whether it is the ideal long-term antiviral program remains to be studied.